{"url_path":"/sec/mbrx/8-k/2026-06-05/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1659617/0001437749-26-019660-index.html","accession_number":"0001437749-26-019660","cik":"0001659617","ticker":"MBRX","issuer_name":"Moleculin Biotech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1659617/0001437749-26-019660-index.html","primary_entity_key":"0001659617","primary_entity_name":"Moleculin Biotech, Inc."},"word_count":79,"has_tables":true,"body_markdown":"**Item 9.01**\n\n**Financial Statements and Exhibits.**\n\n \n\n(d)\n\nExhibits.\n\n \n\n**Exhibit**\n\n**No.**\n\n**Description**\n\n \n\n99.1\n\n[Press Release dated June 5, 2026](ex_972741.htm)\n\n \n\n104\n\nCover page Interactive Data File (formatted as Inline XBRL document)\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n**MOLECULIN BIOTECH, INC.** \n\n \n\n \n \n \n \n\n \n \n \n \n\n \n\nDate:\n\nJune 5, 2026\n\n \n\n \n \n \n \n\n \n\nBy:\n\n/s/ Jonathan P. Foster\n\n \n\n \n \n\nJonathan P. Foster\n\n \n\n \n \nChief Financial Officer"}